Haspels et al. developed a high-throughput assay facilitated by automatic spheroid segmentation using deep learning. Measured differences in treatment response between cisplatin-sensitive and resistant tumors faithfully correspond with expected in vivo responses and the assay is able to discriminate between olaparib-sensitive and resistant tumors.
- Ben Haspels
- Maarten W. Paul
- Maayke M. P. Kuijten
